Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
- Choueiri TK, Powles TB, Albiges L, et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Paper presented at: European Society for Medical Oncology (ESMO) conference; September 9-13, 2022; Paris, France. Accessed November 10, 2022
Disclosure statements are available on the authors' profiles:
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.